Cancer
Malignant Esophageal Neoplasm
CI-CAN-00001127Explore in graph →
Top-level518 active trials6 approved drugs12 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00001127Explore in graph →
Clinical trials
1,926 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (169)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05411133 | Treatment of Cabotamig (ARB202) in Advanced Gastrointestinal Cancer Patients | completed | Phase 1 | 33 | Arbele Pty LtdINDUSTRY | 2 | Mar 19, 2026 | clinicaltrials |
| NCT07482774 | Tumor Microenvironment Changes After Neoadjuvant Chemo-Immunotherapy in Esophageal Squamous Cell Carcinoma(TME-ESCC) | not yet recruiting | — | 12 | Nanjing Medical UniversityOTHER | 0 | Mar 19, 2026 | clinicaltrials |
| NCT02642809 | Pembrolizumab With Locally Delivered Radiation Therapy for the Treatment of Metastatic Esophageal Cancers | completed | Phase 1 | 16 | Washington University School of MedicineOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT03301454 | Study of the Interest of Pursuing or Not the Chemotherapy for Patients With Metastatic Esophageal Cancer(E-DIS2) | terminated | Phase 2 | 15 | Centre Oscar LambretOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT06735638 | Outside the Cage (OTC) Robotic Esophagectomy | not yet recruiting | Phase 1 | 31 | Centre hospitalier de l'Université de Montréal (CHUM)OTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT06335966 | BEST-RPP Pilot: Screening for Esophageal Cancer in Rural Oregon Without an Endoscopy(BEST-RPP) | active not recruiting | — | 110 | OHSU Knight Cancer InstituteOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT07469241 | Study of MRI Guided Personal Chemoradiotherapy and Immunotherapy for Limited Advanced Esophageal Squamous Caicinoma.(FUTURE-3) | not yet recruiting | Phase 2 | 50 | Fudan UniversityOTHER | 0 | Mar 13, 2026 | clinicaltrials |
| NCT06349642 | Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform(ELEPHAS-04) | recruiting | — | 324 | Mayo ClinicOTHER | 1 | Mar 12, 2026 | clinicaltrials |
| NCT07464470 | Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Gastroesophageal Cancers(GENCONCOR-2) | recruiting | — | 30 | Blokhin's Russian Cancer Research CenterOTHER | 1 | Mar 12, 2026 | clinicaltrials |
| NCT00587314 | The Effect of Ablation Therapy on Barrett's Esophagus(ablation IN BE) | enrolling by invitation | — | 600 | Mayo ClinicOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT07104214 | Development and Validation of a Risk Prediction Model for Gastric Retention in Patients Undergoing Sedated Gastroscopy | recruiting | — | 5,000 | Zhejiang UniversityOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT07175155 | Combination of COMBO Endoscopy Oropharyngeal Airway and HFNC Oxygenation in Sedated Gastrointestinal Endoscopy for Morbidly Obese Patients | recruiting | N/A | 410 | Zhejiang UniversityOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT07457528 | Efficacy and Safety of Neo-CRT Plus Serplulimab, Nimotuzumab in Patients With Locally Advanced Resectable ESCC | recruiting | Phase 2 | 46 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT07354295 | Integrating Multimodal AI to Predict Treatment Response and Refine Risk Stratification in Esophageal Cancer （Radiogenomics-Esophagus） | recruiting | — | 1,500 | Shu PengOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT03322267 | Adjuvant Pembrolizumab for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma at High Risk of Recurrence | completed | Phase 2 | 26 | National Taiwan University HospitalOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT07455019 | A Study of Bemosubaiabimab Combined With Anlotinib and Radiotherapy and Chemotherapy for the Treatment of Oligometastatic Esophageal Cancer | recruiting | Phase 2 | 28 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT00899626 | Gastrointestinal Biomarkers in Tissue and Biological Fluid Samples From Colorectal Cancer Patients | recruiting | — | 5,000 | Vanderbilt University Medical CenterOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT04075305 | The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study(MOMENTUM) | recruiting | — | 8,000 | UMC UtrechtOTHER | 9 | Mar 5, 2026 | clinicaltrials |
| NCT04900818 | Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 330 | I-Mab Biopharma US LimitedINDUSTRY | 2 | Mar 5, 2026 | clinicaltrials |
| NCT07448493 | Local Treatment Strategies for Brain Metastases of Gastric and Esophageal Cancer(GASTROBRAIN) | active not recruiting | — | 230 | Blokhin's Russian Cancer Research CenterOTHER | 2 | Mar 4, 2026 | clinicaltrials |
| NCT07446335 | A Phase III Study of First-line Anlotinib Combined With Benmelstobart in Patients With Advanced Esophageal Squamous Cell Carcinoma | not yet recruiting | Phase 3 | 578 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT03403465 | Intratreatment FDG-PET During Radiation Therapy for Gynecologic and Gastrointestinal Cancers | active not recruiting | Phase 2 | 90 | Duke UniversityOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT06356311 | A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)(TroFuse-015) | active not recruiting | Phase 3 | 450 | Merck Sharp & Dohme LLCINDUSTRY | 24 | Feb 27, 2026 | clinicaltrials |
| NCT06452602 | Induction Immunochemotherapy Followed by Concurrent Chemoradiotherapy in Patients With ESCC. | recruiting | Phase 2 | 60 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT07039162 | Study of Tislelizumab Combined With Chemoradiotherapy and Surgery for Unresectable Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 45 | Ming-Yu LienOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT07435454 | Exploratory Clinical Trial of Oral Paclitaxel Plus Radiotherapy in Patients With Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 22 | Jiangsu Cancer Institute & HospitalOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT07437898 | Neoadjuvant Adebrelimab Plus Chemotherapy for Esophageal Cancer: A Clinical Study | recruiting | Phase 2 | 42 | The Affiliated Hospital of Putian UniversityOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT04430738 | Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers | active not recruiting | Phase 2 | 40 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 2 | Feb 24, 2026 | clinicaltrials |
| NCT05438420 | Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 120 | Qurient Co., Ltd.INDUSTRY | 2 | Feb 24, 2026 | clinicaltrials |
| NCT06523374 | A Study of Barrett's Esophagus Patients to Investigate Quality of Life and Fear of Cancer, and Optimize a Risk Model Based on Biomarkers and New Technologies to Better Predict the Development of Cancer(Endeavor-1) | recruiting | N/A | 50 | University Hospital, AntwerpOTHER | 6 | Feb 24, 2026 | clinicaltrials |
| NCT03174275 | Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma | active not recruiting | Phase 2 | 39 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Feb 23, 2026 | clinicaltrials |
| NCT04426669 | A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering | completed | Phase 1 / Phase 2 | 23 | Intima Bioscience, Inc.INDUSTRY | 1 | Feb 23, 2026 | clinicaltrials |
| NCT04258813 | Onco-primary Care Networking to Support TEAM-based Care(ONE TEAM) | active not recruiting | N/A | 313 | Duke UniversityOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT04354064 | Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors | recruiting | — | 100 | Washington University School of MedicineOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT07184047 | Frailty Scales for Predicting Chemotherapy Toxicity in Older Adults With Gastrointestinal Cancers(TOX-FRAIL) | completed | — | 72 | Ankara Etlik City HospitalOTHER_GOV | 1 | Feb 20, 2026 | clinicaltrials |
| NCT03896399 | Laparoscopic Ischemic Conditioning Prior to Esophagectomy(ISCON) | completed | N/A | 22 | UMC UtrechtOTHER | 2 | Feb 19, 2026 | clinicaltrials |
| NCT04868877 | Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination | active not recruiting | Phase 1 / Phase 2 | 194 | Merus B.V.INDUSTRY | 9 | Feb 19, 2026 | clinicaltrials |
| NCT06346080 | Molecular Analysis for Gastro-Esophageal Cancer: Multicenter Discrete Choice Experiment(MAGECmultiDiCE) | recruiting | N/A | 2,200 | KU LeuvenOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT07410676 | EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors(EBNK-ST-001) | recruiting | Phase 1 / Phase 2 | 83 | Essen BiotechOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT07416825 | Inter-Observer Delineation Differences in Esophageal Cancer GTV on MR, CT, and PET/CT Protokol šečerov Ermenc 28dec19 | completed | N/A | 23 | Institute of Oncology LjubljanaOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT05312372 | S095033 in Combination With Paclitaxel as 2nd- or 3rd-line Treatment in Participants With Advanced or Metastatic ESCC | withdrawn | Phase 1 / Phase 2 | 0 | Institut de Recherches Internationales ServierOTHER | 0 | Feb 17, 2026 | clinicaltrials |
| NCT05462873 | A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With Advanced Solid Tumors | terminated | Phase 1 | 30 | Novartis PharmaceuticalsINDUSTRY | 9 | Feb 17, 2026 | clinicaltrials |
| NCT06346054 | Molecular Assessment for Gastro-Esophageal Cancer(MAGEC) | recruiting | N/A | 1,000 | KU LeuvenOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT03993353 | Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer | completed | Phase 2 | 7 | University of California, San DiegoOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT05787522 | Clinical Validation of AI-Assisted Radiotherapy Contouring Software for Thoracic Organs at Risk | completed | — | 500 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT06027515 | Esophageal Cancer Multimodal Prehabilitation Study | completed | N/A | 15 | Massachusetts General HospitalOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT07406815 | The Value of Near-Infrared Fluorescence Imaging in the Protection of the Recurrent Laryngeal Nerve During Minimally Invasive Esophagectomy | not yet recruiting | Phase 3 | 144 | Fujian Medical University Union HospitalOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT06623396 | A Study of Mesothelin-Targeted CAR T-Cell Therapy in People With Esophagogastric Cancer | recruiting | Phase 1 | 18 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT07403435 | Short-course Radiotherapy Combined With Serplulimab and Chemotherapy as Neoadjuvant Treatment for Resectable ESCC | not yet recruiting | Phase 2 | 22 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT00628368 | Biological Factors in Predicting Response to Treatment in Patients With Esophageal Cancer or Rectal Cancer | completed | N/A | 160 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Feb 10, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Mar 19, 2026source: clinicaltrials